Business, energy, technology, markets and global industry news from Business News Today

Casgevy

Features & Analysis

Gene editing can nearly eliminate sickle cell crises. A daily pill may still reach far more patients

Gene therapy can transform sickle cell disease, but etavopivat shows why scalable oral treatments may ultimately reach a much larger patient population.

Read More
Features & Analysis

Risto-cel stopped severe sickle cell crises long enough for Beam to plan a BLA. Why did the stock still fall?

Risto-cel met its pivotal sickle cell endpoint, moving Beam toward a year-end BLA while manufacturing and transplant burden remain decisive.

Read More
Features & Analysis

The liver was the easy organ. Can in-vivo gene editing reach the rest of the human body?

Ex-vivo CRISPR edits cells outside the body before reinfusion. In-vivo editing sends the editing machinery directly into a patient, potentially making treatment simpler but far harder to control.

Read More
Pharma & Biotech

Vertex expands CASGEVY to young children with sickle cell disease and beta thalassemia

Explore how the FDA’s CASGEVY age expansion could reshape early gene therapy for sickle cell disease and beta thalassemia. Read more.

Read More
Features & Analysis

Can non-viral gene therapies solve the safety problem holding back genetic medicine?

Viral vectors built gene therapy’s first era. Safety, redosing and manufacturing pressure are pushing non-viral platforms into the spotlight.

Read More